Overview: Initial test, a single-arm, open-label 1st-in-human proof-of-concept study in adults with distal radius fractures.

Novadip Biosciences’s bone grafting material NVDX3 has seen all patients achieve bone fracture union in a 12-month Phase Ib/IIa proof-of-concept study. The Belgian company’s NVDX3-CLN01 (NCT05987033) ...

Hailed as one of the most important feats of British engineering in the last 50 years, Queen Mary researchers developed a range of cost-effective synthetic bone graft materials. These innovative ...

The growing prevalence of orthopaedic conditions is boosting the market’s demand. South Korea’s bone graft and substitutes market is projected to expand at a compound annual growth rate of 4% ...

4, 2024 — Researchers have developed a revolutionary bone graft substitute inspired by coral which not only promotes faster healing but dissolves naturally in the body after the repair is ...

ALACHUA, Fla., February 3, 2025 - Evergen ("the Company"), a leading CDMO pushing the boundaries of innovation and tissue engineering to meet patient needs in regenerative medicine, announces the ...

A bone marrow transplant process co-developed by investigators at the Johns Hopkins ... Following the transplant, they are ...

THIRUVANANTHAPURAM: Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) has launched two innovative drug-eluting bone graft products. The products were unveiled by ...

OsteoFlo HydroFiber represents a disruptive advancement in orthopedic and spine surgery, offering surgeons a highly effective synthetic bone graft option that may enhance patient outcomes.